TKG Healthcare Private Limited, a subsidiary of The Kinetix Group, organized a collaborative educational program between NYC’s Mount Sinai Health and India’s Apollo Hospitals in Chennai, Deli and Hyderabad from March 24th-March 26th. The program, “Emerging Liver Disease Implications and Value,” was led by both Mount Sinai and Apollo faculty, and reached over 300 health care professionals to share best practices in treating nonalcoholic fatty liver disease (NAFLD), more specifically nonalcoholic steatohepatitis (NASH). Attendees included key Indian healthcare stakeholders in government, public policy, community leadership organizations, and health systems.
The continual objectives of the Mount Sinai/Apollo partnership to improve care delivery for non-alcoholic fatty liver disease include the following:
- Provide a platform to promote understanding of the Indian and US healthcare delivery of NASH and hepatitis.
- Establish a foundational, international model to share clinical delivery insights and best practices for healthcare professionals.
- Evaluate clinical research and real world evidence study capabilities.
“This inaugural symposium along with Apollo Hospital and Mount Sinai will provide an opportunity to share insights amongst leading faculty members and will ultimately drive the adoption of an optimal care delivery model for NASH. We believe this is a first-of-its-kind offering for the industry.” – John Strapp Jr., CEO of The Kinetix Group
The Kinetix Group looks forward to continued collaboration with Mount Sinai Health and Apollo Hospitals to address the burgeoning public health issue of NAFLD and NASH, which is growing in prevalence in both the U.S. and India. The company is also excited by sustained expansion of its Dublin office and other international business partnerships in 2017.